In addition, inhibition of SLC6A20 activity by pharmacological or molecular biological methods and consequent increases in brain glycine levels and NMDAR activity could be a potential strategy for the treatment of brain disorders involving NMDAR hypofunction such as schizophrenia and autism spectrum disorders. The gene discussed is SLC6A20; the disease is brain disorder.